JP2020530002A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020530002A5 JP2020530002A5 JP2020505912A JP2020505912A JP2020530002A5 JP 2020530002 A5 JP2020530002 A5 JP 2020530002A5 JP 2020505912 A JP2020505912 A JP 2020505912A JP 2020505912 A JP2020505912 A JP 2020505912A JP 2020530002 A5 JP2020530002 A5 JP 2020530002A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- dlbcl
- antibody
- medicament according
- rituximab
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 25
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 18
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 17
- 238000000034 method Methods 0.000 claims 11
- 108090000623 proteins and genes Proteins 0.000 claims 10
- 229960004641 rituximab Drugs 0.000 claims 10
- 230000014509 gene expression Effects 0.000 claims 8
- 229960003347 obinutuzumab Drugs 0.000 claims 8
- 229940079593 drug Drugs 0.000 claims 4
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims 3
- 108091012583 BCL2 Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 3
- 230000004083 survival effect Effects 0.000 claims 3
- 102100024133 Coiled-coil domain-containing protein 50 Human genes 0.000 claims 2
- 102100039299 Cyclic AMP-responsive element-binding protein 3-like protein 2 Human genes 0.000 claims 2
- 101000910772 Homo sapiens Coiled-coil domain-containing protein 50 Proteins 0.000 claims 2
- 101000745624 Homo sapiens Cyclic AMP-responsive element-binding protein 3-like protein 2 Proteins 0.000 claims 2
- 101001011441 Homo sapiens Interferon regulatory factor 4 Proteins 0.000 claims 2
- 101001005101 Homo sapiens LIM domain-containing protein 1 Proteins 0.000 claims 2
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 claims 2
- 101000593398 Homo sapiens Myb-related protein A Proteins 0.000 claims 2
- 101000998596 Homo sapiens NADH-cytochrome b5 reductase 2 Proteins 0.000 claims 2
- 101000712725 Homo sapiens Ras-related protein Rab-7L1 Proteins 0.000 claims 2
- 101001001648 Homo sapiens Serine/threonine-protein kinase pim-2 Proteins 0.000 claims 2
- 101000693262 Homo sapiens Sphingosine 1-phosphate receptor 2 Proteins 0.000 claims 2
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 claims 2
- 102100030126 Interferon regulatory factor 4 Human genes 0.000 claims 2
- 102100026033 LIM domain-containing protein 1 Human genes 0.000 claims 2
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 claims 2
- 102100034711 Myb-related protein A Human genes 0.000 claims 2
- 102100033168 NADH-cytochrome b5 reductase 2 Human genes 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 102100033100 Ras-related protein Rab-7L1 Human genes 0.000 claims 2
- 102100036120 Serine/threonine-protein kinase pim-2 Human genes 0.000 claims 2
- 102100025749 Sphingosine 1-phosphate receptor 2 Human genes 0.000 claims 2
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- 229920001542 oligosaccharide Polymers 0.000 claims 2
- 150000002482 oligosaccharides Chemical class 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102100033900 Ankyrin repeat and SOCS box protein 13 Human genes 0.000 claims 1
- 102100021975 CREB-binding protein Human genes 0.000 claims 1
- 102100029713 E3 ubiquitin-protein ligase TRIM56 Human genes 0.000 claims 1
- 206010064571 Gene mutation Diseases 0.000 claims 1
- 102100038885 Histone acetyltransferase p300 Human genes 0.000 claims 1
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 claims 1
- 101000925512 Homo sapiens Ankyrin repeat and SOCS box protein 13 Proteins 0.000 claims 1
- 101000896987 Homo sapiens CREB-binding protein Proteins 0.000 claims 1
- 101000795363 Homo sapiens E3 ubiquitin-protein ligase TRIM56 Proteins 0.000 claims 1
- 101000882390 Homo sapiens Histone acetyltransferase p300 Proteins 0.000 claims 1
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 claims 1
- 101000852593 Homo sapiens Inositol-trisphosphate 3-kinase B Proteins 0.000 claims 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 1
- 101001005668 Homo sapiens Mastermind-like protein 3 Proteins 0.000 claims 1
- 101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 claims 1
- 101000609379 Homo sapiens Pre-mRNA-splicing factor ISY1 homolog Proteins 0.000 claims 1
- 101000743768 Homo sapiens R3H domain-containing protein 1 Proteins 0.000 claims 1
- 101001099877 Homo sapiens Ras-related protein Rab-43 Proteins 0.000 claims 1
- 101000701876 Homo sapiens Serpin A9 Proteins 0.000 claims 1
- 101000648507 Homo sapiens Tumor necrosis factor receptor superfamily member 14 Proteins 0.000 claims 1
- 101000777156 Homo sapiens UBX domain-containing protein 4 Proteins 0.000 claims 1
- 101000803751 Homo sapiens WD repeat-containing protein 55 Proteins 0.000 claims 1
- 108010073807 IgG Receptors Proteins 0.000 claims 1
- 102100036404 Inositol-trisphosphate 3-kinase B Human genes 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 108010018650 MEF2 Transcription Factors Proteins 0.000 claims 1
- 102000055120 MEF2 Transcription Factors Human genes 0.000 claims 1
- 102100025134 Mastermind-like protein 3 Human genes 0.000 claims 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims 1
- 102000003729 Neprilysin Human genes 0.000 claims 1
- 108090000028 Neprilysin Proteins 0.000 claims 1
- 102100038479 Ras-related protein Rab-43 Human genes 0.000 claims 1
- 102100030420 Serpin A9 Human genes 0.000 claims 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims 1
- 102100031308 UBX domain-containing protein 4 Human genes 0.000 claims 1
- 102100035132 WD repeat-containing protein 55 Human genes 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 238000005516 engineering process Methods 0.000 claims 1
- 210000001280 germinal center Anatomy 0.000 claims 1
- 230000005865 ionizing radiation Effects 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000005945 translocation Effects 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023136335A JP2023179425A (ja) | 2017-08-08 | 2023-08-24 | Ｄｌｂｃｌ患者サブグループのオビヌツズマブ治療 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762542489P | 2017-08-08 | 2017-08-08 | |
| US62/542,489 | 2017-08-08 | ||
| PCT/EP2018/071462 WO2019030260A1 (en) | 2017-08-08 | 2018-08-08 | OBINUTUZUMAB TREATMENT OF A DLBCL PATIENT SUBGROUP |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023136335A Division JP2023179425A (ja) | 2017-08-08 | 2023-08-24 | Ｄｌｂｃｌ患者サブグループのオビヌツズマブ治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020530002A JP2020530002A (ja) | 2020-10-15 |
| JP2020530002A5 true JP2020530002A5 (OSRAM) | 2021-09-16 |
| JP7418322B2 JP7418322B2 (ja) | 2024-01-19 |
Family
ID=63209389
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020505912A Active JP7418322B2 (ja) | 2017-08-08 | 2018-08-08 | Ｄｌｂｃｌ患者サブグループのオビヌツズマブ治療 |
| JP2023136335A Pending JP2023179425A (ja) | 2017-08-08 | 2023-08-24 | Ｄｌｂｃｌ患者サブグループのオビヌツズマブ治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023136335A Pending JP2023179425A (ja) | 2017-08-08 | 2023-08-24 | Ｄｌｂｃｌ患者サブグループのオビヌツズマブ治療 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11597772B2 (OSRAM) |
| EP (1) | EP3665196B1 (OSRAM) |
| JP (2) | JP7418322B2 (OSRAM) |
| KR (1) | KR102799421B1 (OSRAM) |
| CN (2) | CN111032692A (OSRAM) |
| AU (1) | AU2018314765C1 (OSRAM) |
| CA (1) | CA3071618A1 (OSRAM) |
| CR (1) | CR20200061A (OSRAM) |
| ES (1) | ES2933256T3 (OSRAM) |
| IL (1) | IL272418B2 (OSRAM) |
| MA (1) | MA49830A (OSRAM) |
| MX (1) | MX2020001493A (OSRAM) |
| MY (1) | MY202382A (OSRAM) |
| PE (1) | PE20200738A1 (OSRAM) |
| PL (1) | PL3665196T3 (OSRAM) |
| SG (1) | SG11202000985XA (OSRAM) |
| TW (1) | TWI772488B (OSRAM) |
| UA (1) | UA126204C2 (OSRAM) |
| WO (1) | WO2019030260A1 (OSRAM) |
| ZA (1) | ZA202000680B (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12227567B2 (en) | 2017-07-25 | 2025-02-18 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| MX2020001493A (es) * | 2017-08-08 | 2020-03-24 | Hoffmann La Roche | Tratamiento con obinutuzumab nuevo subgrupo de pacientes con nuevo linfoma de celulas b grandes difusas (dlbcl). |
| WO2020092427A1 (en) * | 2018-10-29 | 2020-05-07 | Tigatx, Inc. | COMPOSITIONS AND METHODS COMPRISING IgA ANTIBODY CONSTRUCTS |
| CN116063520A (zh) | 2019-01-30 | 2023-05-05 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| CN116157151A (zh) | 2020-05-26 | 2023-05-23 | 真和制药有限公司 | 通过阻断半乳凝素-3治疗炎性疾病的方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2957177B2 (ja) | 1986-03-20 | 1999-10-04 | 日本電気株式会社 | マイクロコンピユータ |
| DE69303494T2 (de) | 1992-11-13 | 1997-01-16 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| JP3919235B2 (ja) | 1997-06-13 | 2007-05-23 | ジェネンテク，インコーポレイテッド | 抗体製剤 |
| BRPI0416262B1 (pt) | 2003-11-05 | 2022-04-12 | Roche Glycart Ag | Anticorpo anti-cd20 humano tipo ii humanizado, seu método de produção, seus usos, bem como polinucleotídeo isolado, vetor de expressão e composição farmacêutica |
| GB0718684D0 (en) * | 2007-09-24 | 2007-10-31 | Roche Products Ltd | Treatment method |
| US20130195843A1 (en) * | 2010-06-23 | 2013-08-01 | British Columbia Cancer Agency Branch | Biomarkers for Non-Hodgkin Lymphomas and Uses Thereof |
| DE102013222576A1 (de) | 2013-11-06 | 2015-05-07 | BSH Bosch und Siemens Hausgeräte GmbH | Haushaltsgerät |
| AU2014346788B8 (en) * | 2013-11-06 | 2021-01-28 | Arizona Board Of Regents On Behalf Of The Unviersity Of Arizona | Method for subtyping lymphoma types by means of expression profiling |
| WO2015067586A2 (en) | 2013-11-07 | 2015-05-14 | F. Hoffmann-La Roche Ag | Combination therapy of an anti cd20 antibody with a btk inhibitor |
| EP3122900A1 (en) * | 2014-03-24 | 2017-02-01 | F. Hoffmann-La Roche AG | Cancer treatment with c-met antagonists and correlation of the latter with hgf expression |
| US20160137727A1 (en) * | 2014-09-15 | 2016-05-19 | Genentech, Inc. | Antibody formulations |
| EP3262071B8 (en) * | 2014-09-23 | 2022-05-18 | F. Hoffmann-La Roche AG | Method of using anti-cd79b immunoconjugates |
| CA2986437A1 (en) * | 2015-06-08 | 2016-12-15 | Debiopharm International, S.A. | Anti-cd37 immunoconjugate and anti-cd20 antibody combinations |
| MX2017016651A (es) | 2015-06-24 | 2018-05-14 | Hoffmann La Roche | Anticuerpos contra csf-1r humano para su uso en la induccion de linfocitosis en linfomas o leucemias. |
| EP3178848A1 (en) * | 2015-12-09 | 2017-06-14 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies |
| KR102850929B1 (ko) | 2015-12-09 | 2025-08-27 | 에프. 호프만-라 로슈 아게 | 항-약물 항체의 형성을 감소시키기 위한 ii형 항-cd20 항체 |
| MX2020001493A (es) * | 2017-08-08 | 2020-03-24 | Hoffmann La Roche | Tratamiento con obinutuzumab nuevo subgrupo de pacientes con nuevo linfoma de celulas b grandes difusas (dlbcl). |
-
2018
- 2018-08-08 MX MX2020001493A patent/MX2020001493A/es unknown
- 2018-08-08 CR CR20200061A patent/CR20200061A/es unknown
- 2018-08-08 TW TW107127631A patent/TWI772488B/zh active
- 2018-08-08 PL PL18755421.7T patent/PL3665196T3/pl unknown
- 2018-08-08 CN CN201880051243.4A patent/CN111032692A/zh active Pending
- 2018-08-08 UA UAA202001356A patent/UA126204C2/uk unknown
- 2018-08-08 ES ES18755421T patent/ES2933256T3/es active Active
- 2018-08-08 IL IL272418A patent/IL272418B2/en unknown
- 2018-08-08 JP JP2020505912A patent/JP7418322B2/ja active Active
- 2018-08-08 MA MA049830A patent/MA49830A/fr unknown
- 2018-08-08 AU AU2018314765A patent/AU2018314765C1/en active Active
- 2018-08-08 CN CN202411647297.0A patent/CN119798437A/zh active Pending
- 2018-08-08 WO PCT/EP2018/071462 patent/WO2019030260A1/en not_active Ceased
- 2018-08-08 PE PE2020000199A patent/PE20200738A1/es unknown
- 2018-08-08 MY MYPI2020000328A patent/MY202382A/en unknown
- 2018-08-08 KR KR1020207006102A patent/KR102799421B1/ko active Active
- 2018-08-08 CA CA3071618A patent/CA3071618A1/en active Pending
- 2018-08-08 EP EP18755421.7A patent/EP3665196B1/en active Active
- 2018-08-08 SG SG11202000985XA patent/SG11202000985XA/en unknown
-
2020
- 2020-01-31 ZA ZA2020/00680A patent/ZA202000680B/en unknown
- 2020-02-06 US US16/784,021 patent/US11597772B2/en active Active
-
2023
- 2023-02-02 US US18/163,810 patent/US20230348611A1/en active Pending
- 2023-08-24 JP JP2023136335A patent/JP2023179425A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020530002A5 (OSRAM) | ||
| US12235270B2 (en) | Depleting tumor-specific tregs | |
| JP7295283B2 (ja) | Ｆｌｔ３ｌ－ｆｃ融合タンパク質及び使用方法 | |
| JP2022543817A (ja) | プレボテラ・ヒスチコラ（Ｐｒｅｖｏｔｅｌｌａ ｈｉｓｔｉｃｏｌａ）を使用して乾癬及びアトピー性皮膚炎を処置する組成物及び方法 | |
| CN111052247B (zh) | 用于由经归一化生物标志物评分鉴定癌症治疗的系统和方法 | |
| Mease et al. | Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial. | |
| US10683352B1 (en) | Methods for treating cancer using GRM8 inhibitors | |
| CN115551537A (zh) | 肿瘤细胞疫苗 | |
| Wiendl et al. | Targeting immune cell trafficking–insights from research models and implications for future IBD therapy | |
| Carrozzo et al. | Oral mucosal injury caused by targeted cancer therapies | |
| MX2015004563A (es) | Biomarcadores predictivos para respuesta clinica para acetato de glatiramero. | |
| EP4064862A1 (en) | Designed bacterial compositions and uses thereof | |
| JP2023179425A (ja) | Ｄｌｂｃｌ患者サブグループのオビヌツズマブ治療 | |
| EP4566667A2 (en) | Treatment of cardiometabolic disease with inhibitors of type i interferon signalling | |
| Oh et al. | The rate of decrease in the disease activity of rheumatoid arthritis during treatment with adalimumab depends on the dose of methotrexate | |
| Nicolò et al. | Translational characterization of immune pathways in inflammatory bowel disease: Insights for targeted treatments | |
| JP6860652B2 (ja) | 医薬組成物 | |
| TW201639591A (zh) | 使用抗格拉替雷醋酸鹽抗體反應之方法 | |
| Garcia De La Pena et al. | Polymorphism rs2275913 of Interleukin-17A is related to more intensive therapy with disease-modifying anti rheumatic drugs in Rheumatoid Arthritis Mexican patients. | |
| US20240368294A1 (en) | Cd40l-specific tn3-derived scaffolds for use in the treatment and prevention of rheumatoid arthritis | |
| Chowdhury | The longitudinal effects of rituximab in the Trial for Anti-B Cell Therapy in Primary Sjögren’s Syndrome (TRACTISS). | |
| Pan et al. | Beyond the joints: mechanistic insights and multidisciplinary strategies for spondyloarthritis-associated uveitis | |
| CN118076369A (zh) | Cd40l特异性tn3衍生支架及其用于治疗和预防类风湿性关节炎的方法 | |
| Jaka et al. | Buccal Lymphoma: A Case Report | |
| JP2025526439A (ja) | シグナル調節タンパク質アルファ（ＳＩＲＰα）遺伝子の発現を阻害するための組成物及び方法 |